These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 20230328)
1. Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Hellmeyer L; Boekhoff J; Hadji P Gynecol Endocrinol; 2010 Oct; 26(10):725-8. PubMed ID: 20230328 [TBL] [Abstract][Full Text] [Related]
2. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571 [TBL] [Abstract][Full Text] [Related]
3. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Stroup JS; Rivers SM; Abu-Baker AM; Kane MP Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760 [TBL] [Abstract][Full Text] [Related]
4. Complicated osteoporosis in progeroid syndrome: treatment with teriparatide. Iglesias Bolaños P; Guijarro de Armas G; Civantos Modino S; Vega Piñero B; Pavón de Paz I; Monereo Megías S J Clin Densitom; 2012; 15(1):116-9. PubMed ID: 22154431 [TBL] [Abstract][Full Text] [Related]
5. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. Obermayer-Pietsch BM; Marin F; McCloskey EV; Hadji P; Farrerons J; Boonen S; Audran M; Barker C; Anastasilakis AD; Fraser WD; Nickelsen T; J Bone Miner Res; 2008 Oct; 23(10):1591-600. PubMed ID: 18505369 [TBL] [Abstract][Full Text] [Related]
6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968 [TBL] [Abstract][Full Text] [Related]
7. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide. Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544 [TBL] [Abstract][Full Text] [Related]
8. Treatment of osteoporosis with parathyroid hormone and teriparatide. Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744 [TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337 [TBL] [Abstract][Full Text] [Related]
11. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis]. Lems WF; Hamdy NA; Netelenbos JC Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613 [TBL] [Abstract][Full Text] [Related]
12. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Rossi CM; Di Comite G N Engl J Med; 2008 Mar; 358(12):1302; author reply 1303-4. PubMed ID: 18354112 [No Abstract] [Full Text] [Related]
14. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047 [TBL] [Abstract][Full Text] [Related]
15. [Teriparatide--new value in osteoporosis treatment: treatment guidelines]. Korsić M; Kastelan D Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560 [TBL] [Abstract][Full Text] [Related]
16. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Adachi JD; Hanley DA; Lorraine JK; Yu M Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204 [TBL] [Abstract][Full Text] [Related]
17. [Advances in the field of osteoporosis]. Vignot E; Delmas PD Rev Prat; 2007 Oct; 57(15):1629-31. PubMed ID: 18080418 [No Abstract] [Full Text] [Related]
18. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369 [TBL] [Abstract][Full Text] [Related]
19. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis]. Toenders WG Ned Tijdschr Geneeskd; 2006 Apr; 150(15):879; author reply 879. PubMed ID: 16676521 [No Abstract] [Full Text] [Related]
20. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. Tashjian AH; Gagel RF J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282 [No Abstract] [Full Text] [Related] [Next] [New Search]